Eupraxia Pharmaceuticals (NASDAQ:EPRX) Cut to Strong Sell at Wall Street Zen

Posted by on Oct 17th, 2026

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

EPRX has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. Oppenheimer initiated coverage on Eupraxia Pharmaceuticals in a report on Thursday, June 25th. They set an “outperform” rating and a $17.00 target price on the stock. Wedbush started coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. They set an “outperform” rating and a $17.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Eupraxia Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $17.80.

Read Our Latest Report on Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Trading Down 2.2%

Shares of NASDAQ:EPRX opened at $6.62 on Friday. The company’s 50-day moving average price is $7.53 and its two-hundred day moving average price is $7.02. Eupraxia Pharmaceuticals has a one year low of $5.25 and a one year high of $9.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The stock has a market capitalization of $430.43 million, a PE ratio of -6.49 and a beta of 0.83.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. On average, equities analysts forecast that Eupraxia Pharmaceuticals will post -0.85 EPS for the current fiscal year.

Institutional Trading of Eupraxia Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Persistent Asset Partners Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth approximately $25,000. BlackRock Inc. bought a new position in Eupraxia Pharmaceuticals in the second quarter worth approximately $40,000. AXQ Capital LP increased its holdings in shares of Eupraxia Pharmaceuticals by 34.2% during the second quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock valued at $140,000 after acquiring an additional 5,390 shares in the last quarter. Cibc World Market Inc. acquired a new position in shares of Eupraxia Pharmaceuticals during the second quarter worth approximately $1,539,000. Finally, Royal Bank of Canada lifted its holdings in shares of Eupraxia Pharmaceuticals by 33.2% in the 1st quarter. Royal Bank of Canada now owns 261,376 shares of the company’s stock worth $1,893,000 after purchasing an additional 65,099 shares in the last quarter.

About Eupraxia Pharmaceuticals

(Get Free Report)

Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions.

Eupraxia’s lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee.

Featured Stories

Analyst Recommendations for Eupraxia Pharmaceuticals (NASDAQ:EPRX)

Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.